News & Updates
Filter by Specialty:
Immunotherapy, TACE-based regimen may reshape HCC treatment landscape
In the EMERALD-1 trial, durvalumab plus bevacizumab (D+B) combined with transarterial chemoembolization (TACE) improved progression-free survival (PFS) in individuals with unresectable hepatocellular carcinoma (HCC) eligible for embolization.
Immunotherapy, TACE-based regimen may reshape HCC treatment landscape
13 Feb 2024
IV ginkgo may boost brain recovery after stroke
In a placebo-controlled trial, active components of Ginkgo biloba given intravenously for 14 days helps improve cognitive recovery among patients following an acute ischaemic stroke.
IV ginkgo may boost brain recovery after stroke
13 Feb 2024
Idiopathic Parkinson’s disease: Which dopamine agonist is associated with lower risk of impulse control–related behavioural disorders?
In Chinese patients with idiopathic Parkinson’s disease (IPD) on their first dopamine agonist (DA) monotherapy for >6 months, bromocriptine is associated with a lower risk of impulse control–related behavioural disorders (ICRDs) compared with pramipexole and ropinirole, an observational cohort study in Hong Kong has shown. Rotigotine demonstrated a trend towards lower ICRD risk than the latter two DAs.
